Table 1 Patient characteristics, treatment, and univariate analysis results
Number of patients (N = 338) (%) | OS | PCSM | BRFS | |
|---|---|---|---|---|
P value | P value | P value | ||
Age | 0.003 | 0.4 | 0.16 | |
Median | 71(50–85) | |||
≤70 | 157(46.4) | |||
>70 | 181(53.6) | |||
Comorbidity | 0.5 | 0.33 | 0.023 | |
no | 120(35.7) | |||
yes | 218(64.3) | |||
% Positive biopsies | 0.9 | 0.01 | 0.3 | |
< 0.5 | 154(45.6) | |||
≥ 0.5 | 184(54.4) | |||
% Tumor volume | 0.8 | 0.006 | 0.07 | |
< 50% | 150(44.4) | |||
≥ 50% | 188(55.6) | |||
Gleason score | 0.27 | 0.03 | 0.004 | |
< 7 | 90(26.6) | |||
7 | 154(45.6) | |||
> 7 | 94(27.8) | |||
Histological grade group | 0.31 | 0.1 | < 0.0001 | |
1 (≤ 6 GS) | 91(26.9) | |||
2 (3 + 4 GS) | 95(28.1) | |||
3 (4 + 3 GS) | 58(17.2) | |||
4 (8 GS) | 48(14.2) | |||
46(13.6) | ||||
Risk Group | 0.69 | 0.045 | 0.005 | |
intermediate | 131(38.8) | |||
high | 207(61.2) | |||
Initial PSA ng/ml | 0.38 | 0.44 | 0.034 | |
<10 | 75(30) | |||
10–20 | 110(32.5) | |||
>20 | 153(45.5) | |||
Clinical stage | 0.6 | 0.09 | 0.9 | |
T1 | 49(14.5) | |||
T2 | 251(74.3) | |||
T3 | 34(10.2) | |||
T4 | 4(1) | |||
HT use | 0.047 | 0.3 | 0.7 | |
Neoadjuvant HT | 271(80) | |||
concomitant | 59(17.5) | |||
Adjuvant | 8(2.5) | |||
HT period | 0.17 | 0.001 | 0.09 | |
6 month | 89(26.3) | |||
1–3 year | 206(60.9) | |||
> 3 year | 43(12.7) | |||
RT dose | 0.68 | 0.26 | 0.001 | |
70 Gy | 56(16.6) | |||
70-76 Gy | 205(60.7) | |||
>76 | 77(22.8) | |||
RT field | 0.006 | < 0.0001 | < 0.0001 | |
Prostate | 265(78.4) | |||
Pelvis | 73(21.6) | |||
RT Technic | 0.1 | 0.14 | < 0.0001 | |
3DCRT | 208(61.5) | |||
IMRT(VMAT) | 130(38.5) | |||
PSA nadir (ng/mL) | 0.002 | < 0.0001 | < 0.0001 | |
≤ 0.06 | 269(79.6) | |||
> 0.06 | 56(16.6) | |||
Unknown | 13(3.8) | |||
Time to nadir PSA | 0.72 | 0.017 | 0.003 | |
< 12 month | 234(69.2) | |||
≥ 12 month | 92(26.9) | |||
unknown | 13(3.8) |